GLP-3

GLP-3 (10mg)

Triple agonist of the GLP-1, GIP, and glucagon receptors.

Research use only

Concentration
In stock
Standard shipping: $14 flat rate
FAQ

Answers to the most common questions

Peptides for research use are sold under a different regulatory category. They are not prescription medications, so a prescription is not required.
Research Use Only (RUO) is a regulatory designation. It means the product is manufactured and sold for research purposes. Catalyst operates within this framework and does not make therapeutic claims or provide medical advice.
Every batch undergoes identity verification via mass spectrometry, purity analysis via HPLC, and sterility and endotoxin testing. A Certificate of Analysis ships with every order.
No. Catalyst does not provide medical advice, diagnosis, or treatment recommendations. We share what the published science says about the compounds we carry. For questions about personal health, consult a licensed healthcare provider.
Brand-name GLP products are FDA-approved medications sold through pharmacies with a prescription. Catalyst sells research peptides under the RUO framework. The compounds target the same receptors, but the regulatory pathway, pricing structure, and access model are different.
We accept Cash App, Venmo, and PayPal. During checkout, you’ll be directed to your preferred payment app with instructions. A screenshot of your payment confirmation completes your order.
Unopened products may be returned within 30 days of delivery for a full refund. Opened products cannot be returned due to the nature of the compounds. Contact support@catalystexplains.com to initiate a return.

Retatrutide asks a straightforward question: if two receptors work better than one, what happens with three?

A triple agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. Where earlier generations targeted appetite signaling alone, or appetite and metabolic pathways together, this compound adds glucagon-pathway activation, which shifts energy use toward stored fat.

Currently in late-stage (Phase 3) clinical trials. FDA review anticipated 2027.

Compound Retatrutide (LY3437943)
Class Triple receptor agonist
Targets GIP + GLP-1 + Glucagon
Format Lyophilized powder
Concentrations 10mg / 20mg / 30mg
Appearance White to off-white
Purity ≥ 99%
Molecular weight ~4,300 Da

Every batch is tested before release. Documentation ships with the product.

Identity verification

Mass spectrometry confirms the compound matches its stated molecular structure.

Purity analysis

HPLC testing confirms purity at or above the stated threshold.

Sterility and endotoxin

Tested for bacterial endotoxins and sterility prior to release.

Certificate of Analysis

COA included with every order. Batch-specific. Verifiable.

Proper handling preserves compound integrity.

Before mixing Room temperature. Keep dry, away from light.
After mixing Refrigerate at 36-46°F (2-8°C). Do not freeze.
Long-term -20°C (frozen), unmixed only
Light Protect from direct light
Shipping Inspect on arrival